NEW: Find great deals on the latest gadgets and more in the ScienceDaily Store!
Science News
from research organizations

Vaccine For Cytomegalovirus Has Promise

June 4, 1997
Johns Hopkins Children's Center
A vaccine for cytomegalovirus was found to be well tolerated and highly immunogenic in toddlers, according to research at Eastern Virginia Medical School. CMV can cause mononucleosis-type illness, organ rejection, and birth defects.

NORFOLK, Va. -- Researchers at Eastern Virginia Medical School are studying a vaccine that may decrease transmission of cytomegalovirus (CMV) from children to adults.

CMV is a virus that may cause mononucleosis-type illness in healthy adults, severe infections in persons whose immune systems are impaired, organ rejection in transplant recipients and birth defects in infants born to mothers infected during pregnancy.

Douglas K. Mitchell, M.D., assistant professor of pediatrics at EVMS, led the investigation, which was carried out at the Center for Pediatric Research, a joint program of EVMS and Children's Hospital of The King's Daughters.

Mitchell's research, which involved toddlers, used a subunit vaccine combined with a novel adjuvant. The vaccine was produced by Chiron Vaccines, Emeryville, CA. The vaccine was well tolerated and highly immunogenic in the toddlers.

Story Source:

Materials provided by Johns Hopkins Children's Center. Note: Content may be edited for style and length.

Cite This Page:

Johns Hopkins Children's Center. "Vaccine For Cytomegalovirus Has Promise." ScienceDaily. ScienceDaily, 4 June 1997. <>.
Johns Hopkins Children's Center. (1997, June 4). Vaccine For Cytomegalovirus Has Promise. ScienceDaily. Retrieved February 28, 2017 from
Johns Hopkins Children's Center. "Vaccine For Cytomegalovirus Has Promise." ScienceDaily. (accessed February 28, 2017).